Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
MALVERN, Pa., Aug. 8, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty biopharmaceutical company, today announced that Dr. James P. Tursi has been promoted to Chief Medical Officer. Dr. Tursi will report to Armando Anido, Chief Executive Officer and President of Auxilium, and sit on the Auxilium Executive Committee in this role.
Dr. Tursi has been employed at Auxilium since March of 2009 and has been responsible for the oversight of clinical development, clinical operations, biometrics and medical writing. He led a team of 30 individuals involved in clinical activities across several indications. Dr. Tursi played critical roles in the preparation, submissions and approvals of the XIAFLEX® U.S. biologics license application and XIAPEX® European marketing authorization application for Dupuytren's contracture, as well as design of subsequent phase IV clinical trials. He also has led the Peyronie's phase III program development and overseen enrollment of these pivotal clinical studies.
Prior to Auxilium, Dr. Tursi entered the pharmaceutical industry in 2004 as a medical director for Procter and Gamble Pharmaceuticals. He worked on several products and therapeutic areas, which included female sexual dysfunction, overactive bladder, and osteoporosis. His responsibilities included Clinical Development and Medical Affairs. He moved to GlaxoSmithKline Biologicals in 2006 and directed all Medical Affairs responsibilities for cancer vaccines in North America.
Dr. Tursi received his doctor of medicine degree from the Medical College of Pennsylvania. He subsequently completed his training in Gynecology and Obstetrics at the Johns Hopkins Hospital and entered clinical practice in Southern New Jersey caring for indigent patients. He pr